ZA200108847B - 1-Amino triazoloc4,3-a! Quinazoline-5-ones and or -5-thiones inhibiting phosphodiesterase IV - Google Patents

1-Amino triazoloc4,3-a! Quinazoline-5-ones and or -5-thiones inhibiting phosphodiesterase IV

Info

Publication number
ZA200108847B
ZA200108847B ZA200108847A ZA200108847A ZA200108847B ZA 200108847 B ZA200108847 B ZA 200108847B ZA 200108847 A ZA200108847 A ZA 200108847A ZA 200108847 A ZA200108847 A ZA 200108847A ZA 200108847 B ZA200108847 B ZA 200108847B
Authority
ZA
South Africa
Prior art keywords
triazoloc4
thiones
quinazoline
ones
amino
Prior art date
Application number
ZA200108847A
Other languages
English (en)
Inventor
Bernard Gaudilliere
Remi Lavalette
Charles Andrianjara
Francine Breuzard
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ZA200108847B publication Critical patent/ZA200108847B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200108847A 1999-04-28 2001-10-26 1-Amino triazoloc4,3-a! Quinazoline-5-ones and or -5-thiones inhibiting phosphodiesterase IV ZA200108847B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9905398A FR2792938B1 (fr) 1999-04-28 1999-04-28 NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV

Publications (1)

Publication Number Publication Date
ZA200108847B true ZA200108847B (en) 2002-11-27

Family

ID=9544983

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200108847A ZA200108847B (en) 1999-04-28 2001-10-26 1-Amino triazoloc4,3-a! Quinazoline-5-ones and or -5-thiones inhibiting phosphodiesterase IV

Country Status (34)

Country Link
US (1) US6828315B1 (sk)
EP (1) EP1177195B1 (sk)
JP (1) JP2002543199A (sk)
KR (1) KR20020008166A (sk)
CN (1) CN1352644A (sk)
AP (1) AP2001002309A0 (sk)
AT (1) ATE234840T1 (sk)
AU (1) AU4411500A (sk)
BG (1) BG106026A (sk)
BR (1) BR0010072A (sk)
CA (1) CA2388658A1 (sk)
DE (1) DE60001735T2 (sk)
DK (1) DK1177195T3 (sk)
DZ (1) DZ3154A1 (sk)
EA (1) EA004373B1 (sk)
EE (1) EE200100566A (sk)
ES (1) ES2194779T3 (sk)
FR (1) FR2792938B1 (sk)
HK (1) HK1044938B (sk)
HR (1) HRP20010794B1 (sk)
HU (1) HUP0202656A3 (sk)
IL (1) IL146178A0 (sk)
IS (1) IS6114A (sk)
MA (1) MA27343A1 (sk)
MX (1) MXPA01010888A (sk)
NO (1) NO20015235L (sk)
OA (1) OA11875A (sk)
PL (1) PL351951A1 (sk)
PT (1) PT1177195E (sk)
SK (1) SK15322001A3 (sk)
TR (1) TR200103099T2 (sk)
WO (1) WO2000066584A1 (sk)
YU (1) YU76401A (sk)
ZA (1) ZA200108847B (sk)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1199074A1 (en) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
EP1188438A1 (en) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
EP1389468A4 (en) * 2001-05-23 2007-01-10 Tanabe Seiyaku Co COMPOSITIONS PROMOTING THE GUISON OF A BONE FRACTURE
EP1285922A1 (en) * 2001-08-13 2003-02-26 Warner-Lambert Company 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors
FR2832711B1 (fr) * 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
EP1559716B1 (en) * 2002-11-06 2011-09-14 ASKA Pharmaceutical Co., Ltd. Pyrazolonaphthyridine derivative
NZ541232A (en) 2003-01-09 2008-02-29 Astellas Pharma Inc Pyrrolopyridazine derivatives
CN1972684A (zh) * 2004-04-23 2007-05-30 细胞基因公司 用于治疗和控制肺高血压的含有pde4调节剂的组合物以及其使用方法
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
AU2007303846B2 (en) 2006-10-04 2011-03-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists
WO2009013286A1 (en) * 2007-07-24 2009-01-29 Novartis Ag Organic compounds
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
CN103224498B (zh) * 2013-05-07 2015-10-28 陈定奔 两种唑并喹唑啉酮稠杂环的新合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865824A (en) * 1972-03-07 1975-02-11 Icn Pharmaceuticals 2-Aryl-7-substituted pyrazolo {8 1,5{i a{b {9 1,3,5-triazines
US3850932A (en) * 1973-06-28 1974-11-26 Sandoz Ag 5-(2-carboxy and 2-carboalkoxy-phenylamino)-1,2,4-triazolo-quinazolines
IL66835A (en) * 1981-09-24 1988-05-31 Roussel Uclaf 1,4-disubstituted(1,2,4)triazolo(4,3-alpha)quinazolin-5(4h)-one derivatives and their salts,their preparation and pharmaceutical compositions containing them
JPS6028979A (ja) * 1983-07-14 1985-02-14 Dai Ichi Seiyaku Co Ltd イミダゾキナゾリン類化合物
CA2223624C (en) * 1995-06-06 2001-02-20 Pfizer Inc. Tricyclic 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-.alpha.]pyridines
ES2137113B1 (es) * 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.

Also Published As

Publication number Publication date
SK15322001A3 (sk) 2002-11-06
DE60001735T2 (de) 2004-02-05
WO2000066584A1 (fr) 2000-11-09
MA27343A1 (fr) 2005-06-01
HK1044938B (zh) 2003-12-24
HRP20010794A2 (en) 2003-04-30
ATE234840T1 (de) 2003-04-15
PL351951A1 (en) 2003-07-14
CA2388658A1 (en) 2000-11-09
WO2000066584B1 (fr) 2001-02-15
EP1177195B1 (fr) 2003-03-19
DZ3154A1 (fr) 2000-11-09
AU4411500A (en) 2000-11-17
HRP20010794B1 (en) 2004-06-30
EP1177195A1 (fr) 2002-02-06
PT1177195E (pt) 2003-07-31
EA004373B1 (ru) 2004-04-29
KR20020008166A (ko) 2002-01-29
EE200100566A (et) 2003-02-17
TR200103099T2 (tr) 2002-12-23
IS6114A (is) 2001-10-19
NO20015235D0 (no) 2001-10-26
MXPA01010888A (es) 2003-06-24
HUP0202656A2 (hu) 2002-12-28
EA200100994A1 (ru) 2002-06-27
DK1177195T3 (da) 2003-07-14
FR2792938A1 (fr) 2000-11-03
FR2792938B1 (fr) 2001-07-06
OA11875A (en) 2006-03-29
CN1352644A (zh) 2002-06-05
DE60001735D1 (de) 2003-04-24
BR0010072A (pt) 2002-02-05
JP2002543199A (ja) 2002-12-17
AP2001002309A0 (en) 2001-12-31
NO20015235L (no) 2001-12-21
BG106026A (bg) 2002-05-31
IL146178A0 (en) 2002-07-25
HK1044938A1 (en) 2002-11-08
ES2194779T3 (es) 2003-12-01
US6828315B1 (en) 2004-12-07
HUP0202656A3 (en) 2004-12-28
YU76401A (sh) 2004-07-15

Similar Documents

Publication Publication Date Title
ZA200108847B (en) 1-Amino triazoloc4,3-a! Quinazoline-5-ones and or -5-thiones inhibiting phosphodiesterase IV
ZA991946B (en) Pyrazolopyrimidines and pyrazolotriazines.
GB9917199D0 (en) Security system
GB2354102B (en) Security system
EP1210084A4 (en) PYRIDOMORPHINANS, THIENOMORPHINANS AND THEIR USE
ZA992322B (en) Phosphodiesterase iv-inhibiting diazepinoindoles.
EP1222489A4 (en) MULTI-PURPOSE CONTAINER GLASSES
GB2352523B (en) Fluid-gauging systems and methods
EP1270629A4 (en) polyacetal
GB9912817D0 (en) Security system
EP1239747A4 (en) STRAP RETENTION DEVICE
SI1177195T1 (en) 1-AMINO TRIAZOLO 4,3-a! QUINAZOLINE-5-ONES AND OR -5-THIONES INHIBITING PHOSPHODIESTERASE IV
GB9906875D0 (en) Security systems
GB9913222D0 (en) Security system
GB0010435D0 (en) Retaining clip
GB9926860D0 (en) Luggage
GB0018339D0 (en) Stay-put security system
GB9906894D0 (en) Coin clip
GB9929289D0 (en) Retainer
AU140511S (en) Retainer
GB9926329D0 (en) Security systems
GB9922123D0 (en) Phosphodiesterase enzymes
GB9908270D0 (en) Improvements in vehicle security
ZA200001609B (en) Cartridge and charging system incorporating same.
GB0024097D0 (en) Secure transaction systems